Background: Antiparkinsonian pharmacotherapy represents one of the most important expenses related to Parkinson’s disease. The application of generic drugs may help to reduce the economic burden of the disease; however, efficacy and safety of these products have been less studied. Objective: To investigate the efficacy and safety of generic rasagiline (Ralago®) from a clinical perspective. Methods: The Clinical Global Impression of Severity scale was used to rate the most important motor and non-motor symptoms at baseline and 12 weeks after the initiation of Ralago®. Patients also identified symptoms which were the main sources of their disability and distress in everyday life. Results: A total of 499 patients were enrolled (231 females, mean age: 73.2 ± 9.1 years, mean duration of disease: 3.6 ± 3.7 years). Of them, 486 patients completed the study protocol. Both motor and non-motor symptoms showed improvement during 12-week Ralago® treatment. Adverse events were rare, and the majority of them were not considered as serious. Conclusions: The generic rasagiline (Ralago®) is an effective and safe generic product.
 Karlsen, K.H., Tandberg, E., Arsland, D. and Larsen, J.P. (2000) Health Related Quality of Life in Parkinson’s Disease: A Prospective Longitudinal Study. Journal of Neurology, Neurosurgery, and Psychiatry, 69, 584-589.
 Kadastik-Eerme, L., Rosenthal, M., Paju, T., Muldmaa, M. and Taba, P. (2015) Health-Related Quality of Life in Parkinson’s Disease: A Cross-Sectional Study Focusing on Non-Motor Symptoms. Health and Quality of Life Outcomes, 13, 83.
 Aquino, C.C. and Fox, S.H. (2015) Clinical Spectrum of Levodopa-Induced Complications. Movement Disorders: Official Journal of the Movement Disorder Society, 30, 80-89.
 Oertel, W.H., Berardelli, A., Bloem, B.R., et al. (2011) Late (Complicated) Parkinson’s Disease. In: Gilhus, N., Barnes, P.J. and Brainin, M., Eds., European Handbook of Neurological Management, Blackwell Publishing Ltd., Berlin, 237-267.
 Parkinson Study Group (2005) A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations: The PRESTO Study. Archives of Neurology, 62, 241-248.
 Rascol, O., Brooks, D.J., Melamed, E., et al. (2005) Rasagiline as an Adjunct to Levodopa in Patients with Parkinson’s Disease and Motor Fluctuations (LARGO): Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily, Study, a Randomised, Double-Blind, Parallel-Group Trial. The Lancet, 365, 947-954.
 Olanow, C.W., Rascol, O., Hauser, R., et al. (2009) A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson’s Disease. The New England Journal of Medicine, 361, 1268-1278.
 Hattori, N., Takeda, A., Takeda, S., et al. (2018) Rasagiline Monotherapy in Early Parkinson’s Disease: A Phase 3, Randomized Study in Japan. Parkinsonism & Related Disorders, 60, 146-152.
 Sandoval-Rincon, M., Saenz-Farret, M., Miguel-Puga, A., Micheli, F. and Arias-Carrion, O. (2015) Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease. Frontiers in Neurology, 6, 71.
 Hanagasi, H.A., Gurvit, H., Unsalan, P., et al. (2011) The Effects of Rasagiline on Cognitive Deficits in Parkinson’s Disease Patients without Dementia: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Movement Disorders: Official Journal of the Movement Disorder Society, 26, 1851-1858.
 Blandini, F., Armentero, M.T., Fancellu, R., Blaugrund, E. and Nappi, G. (2004) Neuroprotective Effect of Rasagiline in a Rodent Model of Parkinson’s Disease. Experimental Neurology, 187, 455-459.
 Sagi, Y., Mandel, S., Amit, T. and Youdim, M.B. (2007) Activation of Tyrosine Kinase Receptor Signaling Pathway by Rasagiline Facilitates Neurorescue and Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP-Induced Parkinsonism. Neurobiology of Disease, 25, 35-44.
 Spottke, A.E., Reuter, M., Machat, O., et al. (2005) Cost of Illness and Its Predictors for Parkinson’s Disease in Germany. PharmacoEconomics, 23, 817-836.
 Winter, Y., von Campenhausen, S., Reese, J.P., et al. (2010) Costs of Parkinson’s Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study. Neuro-Degenerative Diseases, 7, 365-372.
 Hensler, K., Uhlmann, C., Porschen, T., Benecke, R. and Rosche, J. (2013) Generic Substitution of Antiepileptic Drugs—A Survey of Patients’ Perspectives in Germany and Other German-Speaking Countries. Epilepsy & Behavior, 27, 135-139.
 European Medicines Agency (2010) Guideline on the Investigation of Bioequivalence. London.
 US Food and Drug Administration (2003) Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Consideration.
 Raw, A.S., Lionberger, R. and Yu, L.X. (2011) Pharmaceutical Equivalence by Design for Generic Drugs: Modified-Release Products. Pharmaceutical Research, 28, 1445-1453.
 van der Meersch, A., Dechartres, A. and Ravaud, P. (2011) Quality of Reporting of Bioequivalence Trials Comparing Generic to Brand Name Drugs: A Methodological Systematic Review. PLoS ONE, 6, e23611.
 Bosnyak, E., Herceg, M., Pal, E., et al. (2014) Are Branded and Generic Extended-Release Ropinirole Formulations Equally Efficacious? A Rater-Blinded, Switch-Over, Multicenter Study. Parkinson’s Disease, 2014, Article ID: 158353.
 Martinez-Martin, P., Rojo-Abuin, J.M., Rodriguez-Violante, M., et al. (2016) Analysis of Four Scales for Global Severity Evaluation in Parkinson’s Disease. NPJ Parkinson’s Disease, 2, Article ID: 16007.
 Go, C.L., Rosales, R.L., Schmidt, P., Lyons, K.E., Pahwa, R. and Okun, M.S. (2011) Generic versus Branded Pharmacotherapy in Parkinson’s Disease: Does It Matter? A Review. Parkinsonism & Related Disorders, 17, 308-312.
 Pahwa, R.P.R., Lyons, K.E., Majama, J., McGuire, D., Koller, W., Silverstein, P., et al. (1994) Clinical Experience with Generic Carbidopa Levodopa (G-L) in Patients with Parkinson’s Disease (PD). Neurology, 44, A244.
 Pahwa, R., Marjama, J., McGuire, D., et al. (1996) Pharmacokinetic Comparison of Sinemet and Atamet (Generic Carbidopa/Levodopa, a Single-Dose Study. Movement Disorders: Official Journal of the Movement Disorder Society, 11, 427-430.
 Kasemsap, N., Onsanit, S., Chiewthanakul, P., et al. (2016) Efficacy and Motor Complications of Original and Generic Levodopa in Parkinson’s Disease Treatment. Neuropsychiatric Disease and Treatment, 12, 1185-1189.
 Zhang, Z., Shao, M., Chen, S., et al. (2018) Adjunct Rasagiline to Treat Parkinson’s Disease with Motor Fluctuations: A Randomized, Double-Blind Study in China. Translational Neurodegeneration, 7, 14.
 Martinez-Martin, P., Forjaz, M.J., Cubo, E., Frades, B., de Pedro Cuesta, J. and Members, E.P. (2006) Global versus Factor-Related Impression of Severity in Parkinson’s Disease: A New Clinimetric Index (CISI-PD). Movement Disorders, 21, 208-214.
 Arnold, G., Gasser, T., Storch, A., et al. (2005) High Doses of Pergolide Improve Clinical Global Impression in Advanced Parkinson’s Disease—A Preliminary Open Label Study. Archives of Gerontology and Geriatrics, 41, 239-253.
 Takanashi, M., Shimo, Y., Hatano, T., Oyama, G. and Hattori, N. (2013) Efficacy and Safety of a Once-Daily Extended-Release Formulation of Pramipexole Switched from an Immediate-Release Formulation in Patients with Advanced Parkinson’s Disease: Results from an Open-Label Study. Drug Research, 63, 639-643.